Dataset from A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Avonex® in Subjects With Moderate to Severe Ulcerative Colitis

The primary objective of the study is to evaluate the clinical activity of interferon beta-1a
in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this
study are to determine (i) the safety and tolerability of interferon beta-1a in participants
with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the
Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.

本研究的主要目的为评估干扰素β-1a（interferon beta-1a）在中重度溃疡性结肠炎（ulcerative colitis，UC）受试者中的临床活性。本研究的次要目的为确定：①干扰素β-1a在中重度溃疡性结肠炎（UC）受试者中的安全性与耐受性；②第8周时简易临床结肠炎活动指数（Simple Clinical Colitis Activity Index，SCCAI）评分降低≥3分的受试者占比。